Comprehensive analysis of the relationship between cuproptosis-related genes and esophageal cancer prognosis

Table 1 Demographic characteristics and clinicopathological characteristics

Variables	Total, n = 151	Esophagus cancer, n = 151
		Adenocarcinoma, n = 74	Squamous cell carcinoma, n = 77
Age, yr
Median	60	68.5	57
Interquartile range	(53-72)	(57-77)	(51-63.5)
Sex
Female	22 (14.6%)	11 (14.9%)	11 (14.3%)
Male	129 (85.4%)	63 (85.1%)	66 (85.7%)
AJCC-TNM Stage
Ⅰ	18 (11.9%)	11 (14.9%)	7 (9.1%)
Ⅱ	70 (46.4%)	24 (32.4%)	46 (59.7%)
Ⅲ	51 (33.8%)	31 (41.9%)	20 (26.0%)
Ⅳ	12 (7.9%)	8 (10.8%)	4 (5.2%)
EGFR status
Mutant	5 (3.3%)	3 (4.1%)	2 (2.6%)
Wild-type	146 (96.7%)	71 (95.9%)	75 (97.4%)
KRAS status
Mutant	2 (1.3%)	2 (2.7%)	0 (0)
Wild-type	149 (98.7%)	72 (97.3%)	77 (100%)
BRAF status
Mutant	1 (0.7%)	0 (0)	1 (1.3%)
Wild-type	150 (99.3%)	74 (100%)	76 (98.7)
PIK3CA status
Mutant	14 (9.3%)	4 (5.4%)	10 (13.0%)
Wild-type	137 (90.7%)	70 (94.6%)	67 (87.0%)
OS event
Event	58 (38.4%)	36 (48.6%)	22 (28.6%)
Non-event	93 (61.6%)	38 (51.4%)	55 (71.4%)
OS months
Median	13.4	14.8	13.0
Range	(7.8-22.9)	(7.3-27.5)	(11.0-18.6)
PFS event
Event	73 (48.3%)	38 (51.4%)	35 (45.5%)
Non-event	78 (51.7%)	36 (48.6%)	42 (54.5%)
PFS months
Median	10.7	10.3	10.7
Range	(5.1-18.9)	(5.4-24.5)	(3.7-15.8)

AJCC: American Joint Committee on Cancer; BRAF: v-Raf murine sarcoma viral oncogene homolog B1 genes; EGFR: Epidermal growth factor receptor; KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; OS: Overall survival; PFS: Progression-free survival; PIK3CA: Phosphatidylino-sitol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; TNM: Tumor-node-metastasis.